Hans Olav Melberg

• Anisdahl, Karoline; Lirhus, Sandre Svatun; Medhus, Asle Wilhelm; Moum, Bjørn Allan; Melberg, Hans Olav & Høivik, Marte Lie (2024). Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study. Digestive and Liver Disease. ISSN 1590-8658. doi: 10.1016/j.dld.2024.02.002.
• Melberg, Hans Olav (2023). Nyttig perspektiv på overvektig populasjon. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(13). doi: 10.4045/tidsskr.23.0593.
• Burisch, Johan; Zhao, Mirabella; Odes, Selwyn; De Cruz, Peter; Vermeire, Severine & Bernstein, Charles N [Show all 33 contributors for this article] (2023). The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. 8(5), p. 458–492. doi: 10.1016/S2468-1253(23)00003-1. Full text in Research Archive
• Ødegaard, Kristina Malene; Lirhus, Sandre Svatun; Melberg, Hans Olav; Hallen, Jonas & Halvorsen, Sigrun (2022). Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014–2020. ESC Heart Failure. ISSN 2055-5822. doi: 10.1002/ehf2.14206. Full text in Research Archive
• Zhao, Mirabella; Lirhus, Sandre Svatun; Lördal, Mikael; Langholz, Ebbe; Knudsen, Torben & Voutilainen, Markku [Show all 15 contributors for this article] (2022). Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway. Alimentary Pharmacology and Therapeutics. ISSN 0269-2813. 56(6), p. 989–1006. doi: 10.1111/apt.17145.
• Ødegaard, Kristina Malene; Lirhus, Sandre Svatun; Melberg, Hans Olav; Hallen, Jonas & Halvorsen, Sigrun (2022). A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates. BMC Cardiovascular Disorders. ISSN 1471-2261. 22(1). doi: 10.1186/s12872-022-02522-y. Full text in Research Archive
• Bugge, Christoffer; Kaasa, Stein; Sæther, Erik Magnus; Melberg, Hans Olav & Kristiansen, Ivar Sønbø (2021). What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study. BMJ Open. ISSN 2044-6055. 11(9), p. 1–7. doi: 10.1136/bmjopen-2021-050564.
• Anisdahl, Karoline; Lirhus, Sandre Svatun; Medhus, Asle Wilhelm; Moum, Bjørn; Melberg, Hans Olav & Høivik, Marte Lie (2021). First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. p. 1–7. doi: 10.1080/00365521.2021.1955147. Full text in Research Archive
• Fossmark, Reidar; Olaisen, Maya; Martinsen, Tom Christian & Melberg, Hans Olav (2021). Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therapeutic Advances in Gastroenterology. ISSN 1756-283X. 14, p. 1–10. doi: 10.1177/17562848211021760. Full text in Research Archive Show summary

  Background: Oral 5-aminosalicylic acid (5-ASA) is the mainstay treatment of ulcerative colitis (UC) and therapy with oral 5-ASA is associated with beneficial outcomes. We have examined factors associated with the persistence of oral 5-ASA treatment in a national cohort of UC patients. Methods: Patients with newly diagnosed UC from 2010 to 2014 using oral 5-ASA monotherapy were identified by combining data from the Norwegian Patient Registry and the Norwegian Prescription Database. The median follow-up time was 1029 days. Drug persistence was defined as duration of oral 5-ASA preparation as monotherapy. Non-persistence of a oral 5-ASA preparation as monotherapy was defined as stopping oral 5-ASA, initiation of any further anti-inflammatory treatment including a course of glucocorticoids and a change to another oral 5-ASA preparation. Drug persistence was analyzed using the Kaplan–Meier method and influence of covariates on drug persistence was analyzed with the Cox proportional hazard model. Results: A total of 3421 patients were identified. The overall median 5-ASA drug persistence was 179 days. In univariate analyses, persistence was associated with preparation type and high-dose treatment, while oral glucocorticoid use or hospitalization around the start of oral 5-ASA were associated with shorter 5-ASA persistence. In multivariate analyses, oral glucocorticoids [HR 1.67 (1.54–1.80), p < 0.005] and hospitalization around start of 5-ASA [HR 1.23 (1.14–1.34), p < 0.005] were associated with non-persistence, whereas high dose (⩾3 g/day) 5-ASA was associated with longer persistence [HR 0.68 (0.65–0.71), p < 0.005]. Conclusion: High-dose treatment with oral 5-ASA was associated with longer persistence of oral 5-ASA monotherapy, whereas the presence of factors indicating more severe disease around initiation of 5-ASA monotherapy was associated with a shorter persistence.

• Kverndokk, Snorre & Melberg, Hans Olav (2021). Using fees to reduce bed-blocking: a game between hospitals and long-term care providers. European Journal of Health Economics. ISSN 1618-7598. 22(6), p. 931–949. doi: 10.1007/s10198-021-01299-9.
• Lirhus, Sandre Svatun; Høivik, Marte Lie; Moum, Bjørn; Anisdahl, Karoline & Melberg, Hans Olav (2021). Incidence and prevalence of inflammatory bowel disease in norway and the impact of different case definitions: A nationwide registry study. Clinical Epidemiology. ISSN 1179-1349. 13, p. 287–294. doi: 10.2147/CLEP.S303797. Full text in Research Archive
• Ødegaard, Kristina Malene; Hallen, Jonas; Lirhus, Sandre Svatun; Melberg, Hans Olav & Halvorsen, Sigrun (2020). Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013-2016 . ESC Heart Failure. ISSN 2055-5822. doi: 10.1002/ehf2.12773. Full text in Research Archive
• Melberg, Hans Olav & Asphaug, Lars (2019). Health Economics and Fatty Liver Disease. In Krag, Aleksander & Hansen, Torben (Ed.), The Human Gut-Liver-Axis in Health and Disease. Springer Nature. ISSN 978-3-319-98890-0. p. 81–86. doi: 10.1007/978-3-319-98890-0_5.
• Asphaug, Lars; Thiele, Maja; Krag, Aleksander & Melberg, Hans Olav (2019). Cost‐Effectiveness of Noninvasive Screening for Alcohol‐Related Liver Fibrosis. Hepatology. ISSN 0270-9139. doi: 10.1002/hep.30979.
• Asphaug, Lars & Melberg, Hans Olav (2019). The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway. Medical Decision Making Policy & Practice. ISSN 2381-4683. 4(1), p. 1–19. doi: 10.1177/2381468318821103.
• Kjelle, Elin; Kleven, Linn; Olerud, Hilde M & Melberg, Hans Olav (2018). Cost analysis of mobile radiography services for nursing home residents in Southeast Norway. Journal of Evaluation In Clinical Practice. ISSN 1356-1294. doi: 10.1111/jep.13058. Full text in Research Archive Show summary

  Telemedicine applications, such as a mobile radiography service, provide a new way of organizing healthcare services. In order to provide safe and personalised care for nursing home residents during X‐ray examinations, mobile radiography services have been implemented. The objective of this study was to analyse the costs of X‐ray examinations and treatments for nursing home residents when comparing hospital‐based imaging with a combination of hospital‐based imaging and a mobile radiography service in Southeast Norway. Methods A decision model was developed using the software TreeAge Pro. The model included two alternatives: the mobile radiography service in combination with hospital‐based imaging and hospital‐based imaging alone. The treatment needed based on the examination results could be given either in the nursing home or at the hospital. Probabilities and costs in the model were derived from previous research, various reports, and hospital data from the Southeast region of Norway. Monte Carlo simulations of 1000 residents were run through the model, and statistical analyses were applied. Results The analysis showed a mean cost of €2790 per resident for the hospital‐based service alone. For mobile and hospital‐based services combined, the mean cost was €1946 per resident, including examinations and the immediate treatment given. This difference in costs was significant (p < 0.001). Conclusion A mobile radiography service in nursing homes provides a safe, high quality health care service. The result of this study showed there was a 30% cost‐reduction by implementing the mobile radiography service

• Lirhus, Sandre Svatun; Høivik, Marte Lie; Moum, Bjørn & Melberg, Hans Olav (2018). Regional differences in anti-TNF-a therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 53(8), p. 952–957. doi: 10.1080/00365521.2018.1495258. Full text in Research Archive
• Olsen, Camilla Beck & Melberg, Hans Olav (2018). Did adolescents in Norway respond to the elimination of copayments for general practitioner services? Health Economics. ISSN 1057-9230. 27(7), p. 1120–1130. doi: 10.1002/hec.3660. Full text in Research Archive
• Melberg, Hans Olav (2017). Samhandlingsreformen og kausal inferens . Michael quarterly. Supplement. ISSN 1893-0808. 14(19), p. 119–126. Full text in Research Archive
• Blomqvist, Jan; Kirsimarja, Raitasalo; Melberg, Hans Olav; Schreckenberg, Dirk; Peschel, Christine & klingemann, Justyna [Show all 7 contributors for this article] (2016). Popular images of addiction in five European countries. In Hellman, Matilda; Berridge, Virginia; Duke, Karen & Mold, Alex (Ed.), Concepts of addictive substances and behaviours across time and place. Oxford University Press. ISSN 9780198737797. doi: 10.1093/acprof:oso/9780198737797.003.0010.
• Hagen, Terje P. & Melberg, Hans Olav (2016). Liggetider og reinnleggelser før og etter Samhandlingsreformen. Tidsskrift for omsorgsforskning. ISSN 2387-5976. 2(2), p. 143–158. doi: 10.18261/issn.2387-5984-2016-02-09.
• Melberg, Hans Olav; Olsen, Camilla Beck & Pedersen, Kine (2016). Did hospitals respond to changes in weights of Diagnosis Related Groups in Norway between 2006 and 2013? Health Policy. ISSN 0168-8510. 120(9), p. 992–1000. doi: 10.1016/j.healthpol.2016.07.013. Show summary

  Abstract It has been argued that activity based payment systems make hospitals focus on the diagnostic groups that are most beneficial given costs and reimbursement rates. This article tests this hypothesis by exploring the relationship between changes in the reimbursement rates and changes in the number of registered treatment episodes for all diagnosis-related groups in Norway between 2006 and 2013. The number of treatment episodes can be affected by many factors and in order to isolate the effect of changes in the reimbursement system, we exclude DRGs affected by policy reforms and administrative changes. The results show that hospitals increased the number of admissions in a specific DRG four times more when the reimbursement was increased, relative to the change for DRGs with reduced rates. The direction of the result was consistent across time periods and sub-groups such as surgical vs. medical, and inpatient vs. outpatient DRGs. The effect was smaller, but remained significant after eliminating DRGs that were most likely to be affected by upcoding. Activities that the hospital had little control over, such as the number of births, had small effects, while activity levels in more discretionary categories, for instance mental diseases, were more affected. This demonstrates that contrary to the wishes of policy makers the economic incentives affect hospital reporting and priority setting behavior.

• Olsen, Camilla Beck & Melberg, Hans Olav (2016). Påvirker egenandeler ungdoms legebesøk? Tidsskrift for velferdsforskning. ISSN 0809-2052. 19(1), p. 62–75. doi: 10.18261/issn.2464-3076-2016-01-04. Full text in Research Archive Show summary

  Do co-payments for adolescents affect the number of visits to the physician? To determine the advantages and disadvantages of co-payment for visits to physicians, it is important to quantify the effect of co-payments on the number of consultations. The article uses a change in the co-payment system from 2010, when adolescents between 12 and 15 no longer had to pay a co-payment, in order to estimate the effect of co-payment for this age group. Using a difference-in-difference model and comparing against changes in other age groups, the elimination of co-payments is estimated to have increased GP visits by 13 and 18 percent for males and females respectively. Placebo tests show that the results are robust.

• Bekelman, Justin E.; Halpern, Scott D.; Blankart, Carl Rudolf; Bynum, Julie P.; Cohen, Joachim & Fowler, Robert [Show all 17 contributors for this article] (2016). Comparison of site of death, health care utilization, and hospital expenditures for patients dying With cancer in 7 developed countries. Journal of the American Medical Association (JAMA). ISSN 0098-7484. 315(3), p. 272–283. doi: 10.1001/jama.2015.18603.
• Ottersen, Trygve; Førde, Reidun; Kakad, Meetali; Kjellevold, Alice; Melberg, Hans Olav & Moen, Atle [Show all 8 contributors for this article] (2016). A new proposal for priority setting in Norway: Open and fair. Health Policy. ISSN 0168-8510. 120(3), p. 246–251. doi: 10.1016/j.healthpol.2016.01.012.
• Melberg, Hans Olav & Eriksen, Ida (2015). The effects of introducing an electronic prescription system with no copayments. Health Economics Review. ISSN 2191-1991. p. 2–21. doi: 10.1186/s13561-015-0056-4.
• Medin, Emma; Goude, Fanny; Melberg, Hans Olav; Tediosi, Fabrizio; Belicza, Eva & Peltola, Mikko (2015). European regional differences in all-cause mortality and length of stay for patients with hip fracture. Health Economics. ISSN 1057-9230. 24, p. 53–64. doi: 10.1002/hec.3278.
• Eriksen, Ida & Melberg, Hans Olav (2014). Endringer over tid i legers holdninger til kostnader. In Botten, Grete Synøve; Frich, Jan C; Hagen, Terje P.; Iversen, Tor & Nordby, Halvor (Ed.), Helsetjenestens nye logikk. Akademika forlag. ISSN 978-82-321-0348-5. p. 159–172.
• Gregersen, Fredrik Alexander & Melberg, Hans Olav (2014). I hvor stor grad vil eldrebølgen bidra til økte helsekostnader? -En studie av ulike framskrivningsmetoder for helsekostnader. Samfunnsøkonomen. ISSN 1890-5250. p. 32–37.
• Eriksen, Ida; Melberg, Hans Olav & Bringedal, Berit (2013). Norwegian Physicians' Knowledge of the Prices of Pharmaceuticals: A Survey. PLOS ONE. ISSN 1932-6203. 8(9). doi: 10.1371/journal.pone.0075218.
• Melberg, Hans Olav; Henden, Edmund & Gjelsvik, Olav (2013). Addiction and Responsibility: A Survey of Opinions. Inquiry (Oslo). ISSN 0020-174X. 56(5), p. 558–570. doi: 10.1080/0020174X.2013.806143.
• Henden, Edmund; Melberg, Hans Olav & Røgeberg, Ole (2013). Addiction: choice or compulsion? Frontiers in Psychiatry. ISSN 1664-0640. 4(77), p. 1–11. doi: 10.3389/fpsyt.2013.00077. Full text in Research Archive
• Melberg, Hans Olav; Godager, Geir & Gregersen, Fredrik (2013). Sykehusutgifter mot livets slutt. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 133(8), p. 841–844. doi: 10.4045/tidsskr.12.0802.
• Rockers, Peter C.; Feigl, Andrea B.; Røttingen, John-Arne; Fretheim, Atle; de Ferranti, David & Lavis, John N [Show all 8 contributors for this article] (2012). Study-design selection criteria in systematic reviews of effectiveness of health systems interventions and reforms: A meta-review. Health Policy. ISSN 0168-8510. 104(3), p. 206–214. doi: 10.1016/j.healthpol.2011.12.007.
• Melberg, Hans Olav & Kjekshus, Lars Erik (2012). Innledning. In Melberg, Hans Olav & Kjekshus, Lars Erik (Ed.), Fremtidens Helse-Norge. Fagbokforlaget. ISSN 9788245012088. p. 7–12.
• Melberg, Hans Olav & Kjekshus, Lars Erik (2012). Mot en begrenset rasjonell helsepolitikk? In Melberg, Hans Olav & Kjekshus, Lars Erik (Ed.), Fremtidens Helse-Norge. Fagbokforlaget. ISSN 9788245012088. p. 283–288.
• Melberg, Hans Olav & Lund, Karl Erik (2012). Do smoke-free laws affect revenues in pubs and restaurants? European Journal of Health Economics. ISSN 1618-7598. 13(1), p. 93–99. doi: 10.1007/s10198-010-0287-6. Show summary

  In the debate about laws regulating smoking in restaurants and pubs, there has been some controversy as to whether smoke-free laws would reduce revenues in the hospitality industry. Norway presents an interesting case for three reasons. First, it was among the first countries to implement smoke-free laws, so it is possible to assess the long-term effects. Second, it has a cold climate so if there is a negative effect on revenue one would expect to find it in Norway. Third, the data from Norway are detailed enough to distinguish between revenue from pubs and restaurants. Autoregressive integrated moving average (ARIMA) intervention analysis of bi-monthly observations of revenues in restaurants and pubs show that the law did not have a statistically significant long-term effect on revenue in restaurants or on restaurant revenue as a share of personal consumption. Similar analysis for pubs shows that there was no significant long-run effect on pub revenue.

• Melberg, Hans Olav (2012). Eldrebølgen: bedre enn sitt rykte. In Melberg, Hans Olav & Kjekshus, Lars Erik (Ed.), Fremtidens Helse-Norge. Fagbokforlaget. ISSN 9788245012088. p. 57–66.
• Melberg, Hans Olav; Hakkarainen, Pekka; Houborg, Esben; Jääskeläinen, Marke; Skretting, Astrid & Ramstedt, Mats [Show all 7 contributors for this article] (2011). Measuring the harm of illicit drug use on friends and family. Nordic Studies on Alcohol and Drugs (NAD). ISSN 1455-0725. 28(2), p. 105–121. doi: 10.2478/v10199-011-0012-5. Show summary

  This paper explores different approaches to quantify the human costs related to drug use. The data come from a representative survey of 3092 respondents above the age of 18 in four Nordic capitals: Copenhagen, Helsinki, Oslo and Stockholm. The results show that in most Nordic capitals more than half of the respondents at some time have known and worried about the drug use of somebody they know personally. Moreover, while the average reported harm was about 2 on a scale from 0 to 10, a significant minority (10%) of those knowing drug users indicated that the harm was above 5. Many persons have at some time personally known somebody who uses drugs. This causes significant human harm and should be included in the estimate of the social cost of illegal drugs. These results are relevant in the debate on the size of the drug problem as well as for targeting groups that experience the highest costs.

• Røgeberg, Ole Jørgen & Melberg, Hans Olav (2011). Acceptance of unsupported claims about reality - A blind spot in economics. Journal of Economic Methodology. ISSN 1350-178X. 18(1), p. 29–52. doi: 10.1080/1350178X.2011.556817. Show summary

  Do economists accept absurd and unsupported claims about reality, and if so, why? We define four types of claims commonly made in economics that require different types of evidence, and show examples of each from the rational addiction literature. Claims about real world causal mechanisms and welfare effects seem poorly supported. A survey mailed to all researchers with peer-reviewed work on rational addiction theory provides some evidence that criteria for evaluating claims of pure theory and statistical prediction are better understood than those needed for claims of causality or welfare analysis. We suggest that unsupported claims about real world causality or welfare may be accepted in parts of economics provided they derive from a formally correct model consistent with certain types of (often aggregate) data. The rational addiction literature illustrates that this can lead to absurd and unjustified claims being made and accepted in even highly-ranked journals.

• Melberg, Hans Olav (2011). Measuring the human costs of drug use for friends and family of drug users. The results from a survey in four Nordic capitals. Nordic Studies on Alcohol and Drugs (NAD). ISSN 1455-0725. 28(2), p. 105–121.
• Melberg, Hans Olav & Humpreys, Keith (2010). Ineligibility and refusal to participate in randomised trials of treatments for drug dependence. Drug and Alcohol Review. ISSN 0959-5236. 29(2), p. 193–201.
• Melberg, Hans Olav (2010). Hva tror legene en MR-undersøkelse koster? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 130(6), p. 598–600.
• Melberg, Hans Olav (2010). Conceptual problems with studies of the social cost of alcohol. Nordic Studies on Alcohol and Drugs (NAD). ISSN 1455-0725. 27(4), p. 287–303. Show summary

  Existing studies of the social cost of substance abuse give very different answers. Part of the reason for the differences is that the contributions differ in their definition of costs and the types of costs that are included or excluded from the study. Closer attention to the concept of cost employed in these studies also reveals some weaknesses with many of the existing studies. The policy relevant concept of cost necessarily implies a comparison between all realistically expected consequences (both positive and negative) of two policy alternatives and many cost studies do not use the concept of cost in this way. Finally, it is argued that cost estimates in this area cannot be neutral or scientific because the results depend on our views on when a choice can be characterized as voluntary and rational, how we deal with the problem of inconsistent preferences, and which preferences we consider to be legitimate. Since there is no agreed consensus on these issues, the cost estimate necessarily becomes subjective.

• Melberg, Hans Olav & Røgeberg, Ole Jørgen (2010). Rational addiction theory – A survey of opinions. Journal of Drug Policy Analysis. ISSN 1941-2851. 3(1). doi: 10.2202/1941-2851.1019.
• Melberg, Hans Olav; Jones, Andrew Michael & Bretteville-Jensen, Anne Line (2010). Is cannabis a gateway to hard drugs? Empirical Economics. ISSN 0377-7332. 38(3), p. 583–603. doi: 10.1007/s00181-009-0280-z. Full text in Research Archive Show summary

  The gateway hypothesis proposes that use of cannabis directly increases the risk of consuming hard drugs. We test this controversial, but influential, hypothesis on a sample of cannabis users, exploiting a unique set of drug price data. A flexible approach is developed to identify the causal gateway effect using a bivariate survival model with shared frailty estimated using a latent class approach. The model suggests two distinct groups; a smaller group of “troubled youths” for whom there is a statistically significant gateway effect that more than doubles the hazard of starting to use hard drugs and a larger fraction of youths for whom previous cannabis use has less impact.

• Melberg, Hans Olav (2010). Animal spirits: Fargerik tomhet? Samfunnsøkonomen. ISSN 1890-5250. 64(2), p. 4–10.

View all works in Cristin

• Melberg, Hans Olav & Kjekshus, Lars Erik (2012). Fremtidens Helse-Norge. Fagbokforlaget. ISBN 9788245012088. 292 p.

View all works in Cristin

• Bjørnelv, Gudrun Maria Waaler & Melberg, Hans Olav (2023). Penger, prinsipper og prioritering. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(9). doi: 10.4045/tidsskr.23.0210. Full text in Research Archive
• Fossmark, Reidar; Olaisen, Maya; Martinsen, Tom Christian & Melberg, Hans Olav (2020). P760 Differences in persistence of oral mesalazine preparations as monotherapy in patients with ulcerative colitis . Journal of Crohn's and Colitis. ISSN 1873-9946. 14(January), p. S605–S606. doi: 10.1093/ecco-jcc/jjz203.888.
• Fossmark, Reidar; Olaisen, Maya; Martinsen, Tom Christian & Melberg, Hans Olav (2020). Forskjeller i medikamentoverlevelse mellom perorale mesalazin-preparater som monoterapi ved ulcerøs colitt.
• Bergersen, Linda Hildegard; Bjorvand Bjørkøy, Aasta Marie; Fei Fang, Evandro; Gjelsvik, Olav; Hystad Hove, Lene & Liaaen Jensen, Janicke [Show all 12 contributors for this article] (2020). Vi må kunne tenke nytt om alderdom.
• Melberg, Hans Olav (2019). Value in health: How it is defined and used in priority setting and pricing in Norway. HealthcarePapers. ISSN 1488-917X. 18(3), p. 22–28. doi: 10.12927/hcpap.2019.25929.
• Melberg, Hans Olav (2018). Registertilgang i molboland? Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2018). Obama-reformen – og norsk helsepolitikk. Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2018). Helse-Norge trenger tvil – ikke bare heiarop. Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2018). Hvorfor koster diamanter mer enn vann? Dagens medisin. ISSN 1501-4290.
• Diep, Phoi Phoi; Melberg, Hans Olav; Brinch, Lorentz; Buechner, Jochen; Fløisand, Yngvar & Gedde-Dahl, Thobias [Show all 9 contributors for this article] (2018). Cost-utility of allogeneic hematopoietic stem cell transplantation in Norway. Bone Marrow Transplantation. ISSN 0268-3369. 53(5), p. 657–660. doi: 10.1038/s41409-018-0091-y.
• Kjelle, Elin; Kleven, Linn; Olerud, Hilde M & Melberg, Hans Olav (2018). Radiography on wheels for nursing home residents may reduce healthcare costs.
• Diep, Phoi Phoi; Melberg, Hans Olav; Brinch, Lorentz; Buechner, Jochen; Fløisand, Yngvar & Gedde-Dahl, Thobias [Show all 8 contributors for this article] (2017). Allogeneic hematopoietic stem cell transplantation in Norway 1974-2009: Cost-utility and survival in children and young adults .
• Melberg, Hans Olav (2016). Skal det være en app –eller to? Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2016). Medisiner i ingenmannsland – mens tiden går…. Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2015). Helse og finansiering i Norge.
• Melberg, Hans Olav (2015). Effekter av politiske reformer: Hvorfor går det ofte galt?
• Melberg, Hans Olav (2015). Bruker vi de store pengene på de største problemene?
• Melberg, Hans Olav (2014). Nye regler for prioritering.
• Melberg, Hans Olav (2014). Statsbudsjettet: Raskere og mer private symfonier. Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2014). Jordbær, finansiering - og informasjon i norsk helsevesen. Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2014). Hellig helse - og prislapp på slutten av livet? Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2014). Struts, sykehjem og søppel? Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2014). Intervju om organisering av eldreomsorg i Dagsnytt 18. [Radio]. NRK.
• Melberg, Hans Olav (2014). Are healthcare expenditures increasing faster for the elderly than the rest of the population? Expert review of pharmacoeconomics & outcomes research. ISSN 1473-7167. 14(5), p. 581–583. doi: 10.1586/14737167.2014.919857.
• Melberg, Hans Olav (2014). Prislapp på et liv?
• Melberg, Hans Olav (2014). Effekten av kommunal mediskrivning for utskrivningsklare pasienter.
• Melberg, Hans Olav (2014). Hva driver helsekostnadene?
• Melberg, Hans Olav (2013). Hector Estrup, Jesper Jespersen og Peter Nielsen: Den økonomiske teoriens historie: En introduksjon. Tidsskrift for samfunnsforskning. ISSN 0040-716X. 54(3), p. 396–399.
• Melberg, Hans Olav (2013). Er legemiddelindustrien pill råtten? Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2013). Projecting future health spending and demography.
• Melberg, Hans Olav (2013). The Harkness Experience.
• Melberg, Hans Olav (2013). Vi må eksperimentere mer! Dagens medisin. ISSN 1501-4290.
• Melberg, Hans Olav (2013). Unødvendig forvirring om helseutgifter. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 133(9), p. 935–935. doi: 10.4045/tidsskr.13.0506.
• Melberg, Hans Olav (2013). Den økonomiske teoriens historie: En introduksjon. Tidsskrift for samfunnsforskning. ISSN 0040-716X. 54(3), p. 396–399.
• Melberg, Hans Olav (2013). How does end of life costs and increases in life expectancy affect projections of future health cost?
• Melberg, Hans Olav; Godager, Geir & Gregersen, Fredrik (2013). Sykehusutgifter mot slutten av livet. Dagens medisin. ISSN 1501-4290. 10.
• Kjekshus, Lars Erik & Melberg, Hans Olav (2012). Ti myter om fremtidens helsevesen. Aftenposten (morgenutg. : trykt utg.). ISSN 0804-3116. Show summary

  En avisoverskrift hevdet for en tid tilbake at "helsesektoren kan kræsje om tyve år". Nå skal man kanskje ikke ta avisoverskrifter så tungt, men i stortingsdokumentene om samhandlingsreformen hevdes nesten det samme i et noe mindre fargerikt språk: "En utvikling som truer vår samfunnsøkonomiske bæreevne". Dommedagsprofetier er ikke noe nytt, men helse synes å være et spesielt sterkt fluepapir på profetene. Har de rett? I boken Fremtidens Helse-Norge formidlere femten ulike forfattere sine tanker om fremtidens helsevesen. Innholdet avslører flere myter.

• Godager, Geir; Gregersen, Fredrik & Melberg, Hans Olav (2012). Helseutgifter mot slutten av livet: Hvor viktige er dødsfallsrelaterte utgifter ved beregningen av framtidens helseutgifter?
• Melberg, Hans Olav (2012). Nyttige tilbakemeldinger og provoserende refleksjoner. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 132(14), p. 1641–1641. doi: 10.4045/tidsskr.12.0541.
• Melberg, Hans Olav (2012). End of life costs in Norway and the US.
• Melberg, Hans Olav (2012). Social cost of alcohol: Not always useless even if subjective? Nordic Studies on Alcohol and Drugs (NAD). ISSN 1455-0725. 29(4), p. 35–359. doi: 10.2478/v10199-012-0030-y.
• Melberg, Hans Olav (2012). Bruker Norge mye eller lite til helseformål sammenlignet med andre land? Perspektiv. ISSN 1890-2537. 2012(3), p. 1–20.
• Melberg, Hans Olav (2012). Svindel i amerikansk helsevesen. Anmeldelse av Terry L. Leap “Phantom Billing, Fake Prescriptions, and the High Cost of Medicine: Health Care Fraud and What to Do about It”. Tidsskrift for Den norske legeforening. ISSN 0029-2001. doi: 10.4045/tidsskr.11.1248.
• Melberg, Hans Olav & Hagen, Terje P. (2010). Bruker Norge mye eller lite penger på helse? Overlegen. ISSN 1503-2663. p. 8–9.
• Melberg, Hans Olav (2010). Høye kostnader ved hasjforbud.Kronikk. Dagbladet. ISSN 0805-3766.
• Melberg, Hans Olav; Aas, Eline; Hjort, Ingrid; Vorland, lars; Barra, Mathias & Husbyn, Hallstein [Show all 10 contributors for this article] (2024). Perspektiv og prioriteringer: Rapport fra ekspertgruppen perspektiv i prioritering nedsatt av Helse- og omsorgdepartementet. Helse- og omsorgdepartementet.
• Holden, Steinar; Dunlop, Oona Borghild; Fjærtoft Vik, Styrk; Hjort, Ingrid; Markussen, Simen & Melberg, Hans Olav [Show all 15 contributors for this article] (2022). Holden-IV (covid-19) Hovedrapport: Samfunnsøkonomiske vurderinger av smitteverntiltak. Helse- og Omsorgsdepartementet.
• Tennøe, Tore; Lovett, Hilde; Fosse, Erik; Hatlen, Siri B; Madsen, Steinar & Nassehi, Damoun [Show all 8 contributors for this article] (2019). Kunstig Intelligens og Norske Helsedata. Teknologirådet.
• Lovett, Hilde; Nassehi, Damoun; Fosse, Erik; Hatlen, Siri B; Madsen, Steinar & Melberg, Hans Olav [Show all 7 contributors for this article] (2018). Kunstig Intelligens - Muligheter, Utfordringer og en Plan for Norge. Teknologirådet. ISSN 978-82-92447-95-6.
• Lovett, Hilde; Tennøe, Tore; Dale, Ola; Langtvedt, Nils Jørgen; Melberg, Hans Olav & Madsen, Steinar [Show all 8 contributors for this article] (2016). Mobile Selvtester. Teknologirådet.
• Melberg, Hans Olav & Schøyen, Øivind (2012). Hvordan påvirker redusert skjenketid omsetningen i utelivsbransjen? Nettrapport. Statens institutt for rusmiddelforskning. ISSN 978-82-7171-378-2. Full text in Research Archive
• Lund, Karl Erik; Kvaavik, Elisabeth; Melberg, Hans Olav & Rise, Jostein (2010). Oppdatering av kunnskapsgrunnlaget om forbud mot synlig oppstilling av tobakksvarer. Notat fra Statens institutt for rusmiddelforskning (SIRUS) 20. desember 2010. Statens institutt for rusmiddelforskning. Full text in Research Archive

View all works in Cristin